ReproNovo Appoints Mark Altmeyer as Chairman of the Board

ReproNovo, a biopharmaceutical company based in Switzerland and Denmark, has announced the appointment of Mark Altmeyer as Chairman of the Board. Altmeyer brings over 35 years of leadership experience in the biopharma sector, having worked in both large pharma and biotechnology companies. His expertise spans commercialization strategy, mergers and acquisitions, and international expansion.

Previously, he was the Founder and CEO of Arvelle Therapeutics, where he achieved significant milestones including a $1 billion acquisition by Angelini Pharma. Altmeyer has also held senior roles at companies like Bristol Myers Squibb and Otsuka.

His appointment is seen as a strategic move to advance ReproNovo’s clinical projects, particularly RPN-001 and RPN-002, which focus on fertility and women’s health. Altmeyer's leadership is expected to drive growth and enhance enterprise value, building on his extensive experience in the pharmaceutical industry.